StockData

Tango Therapeutics vs Zentalis Pharmaceuticals

TNGX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TNGX and ZNTL compare

Tango Therapeutics is the larger company, worth 38 times as much as Zentalis Pharmaceuticals ($3.7B against $97.5M).

Tango Therapeutics scores higher on the StockData Score (10 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTNGXZNTL
Size and price
Market cap$3.7B$97.5M
Share price$21.89$1.36
Change, 1 year174%3.0%
Change, 5 years111%−98.2%
Beta (5Y)1.192.18
Employees137106
StockData Score
Total score10 (better)6
Valuation score01 (better)
Growth score2 (better)0
Performance score2 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S68.6×–
P/B3.6×0.7× (better)
FCF yield−3.9% (better)−131%
Fair value$9.68–
Margin of safety−126%–
Growth
Revenue growth (TTM)121%–
Revenue growth, 5Y average52.1%–
Profitability
Operating margin−253%–
Net margin−230%–
FCF margin−268%–
Return on equity−21.3% (better)−66.7%
Financial health
Debt / equity0.000.00
Current ratio50.82 (better)4.82
Altman Z-score44.72 (better)−8.99
Piotroski F-score4 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions127%66.1%
Held by insiders11.7%58.0%
Insider net buying, 12 months−$8.1M$12.8M (better)
Short interest, % of float32.4%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.